Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.
Abstract
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.
참고문헌 (14)
- Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)
- Gomez EV, "The natural history of compensated HCV-related cirrhosis: a prospective long-term study", J Hepatol, 58, pp.434~444 (2013)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Manns MP, "Treating viral hepatitis C: efficacy, side effects, and complications", Gut, 55, pp.1350~1359 (2006)
- Chaudhari S, "Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C", Dig Dis Sci, 49, pp.1000~1006 (2004)
- Tahan V, "Acute pancreatitis attributed to the use of pegylated interferon in a patient with chronic hepatitis C", J Gastrointestin Liver Dis, 16, pp.224~225 (2007)
- Ando K, "Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load", Case Rep Gastroenterol, 3, pp.372~376 (2009)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Tomer Y, "Interferon alpha treatment and thyroid dysfunction", Endocrinol Metab Clin North Am, 36, pp.1051~1066 (2007)
- Zeuzem S, "Pharmacokinetics of peginterferons", Semin Liver Dis, 23, pp.23~28 (2003)
- McHutchison JG, "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection", N Engl J Med, 361, pp.580~593 (2009)
- An S, "2 Case report of acute pancreatitis during the treatment of interferon and ribavirin in chronic hepatitis C", Korean J med, 85(1), pp.91~92 (2013)
- Fried MW, "Side effects of therapy of hepatitis C and their management", Hepatology, 36(5 Suppl 1), pp.S237~S244 (2002)
- Russo MW, "Side effects of therapy for chronic hepatitis C", Gastroenterology, 124, pp.1711~1719 (2003)